A semi-mechanistic exposure–response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases

Jacob Leander1 · Mikael Sunnåker1 · Dinko Rekić1 · Sergey Aksenov2 · Ulf G. Eriksson1 · Susanne Johansson1 · Joanna Parkinson1

Received: 17 August 2020 / Accepted: 2 March 2021 © The Author(s) 2021

Abstract
Verinurad, a uric acid transporter 1 (URAT1) inhibitor, lowers serum uric acid by promoting its urinary excretion. Co-administration with a xanthine oxidase inhibitor (XOI) to simultaneously reduce uric acid production rate reduces the potential for renal tubular precipitation of uric acid, which can lead to acute kidney injury. The combination is currently in development for chronic kidney disease and heart failure. The aim of this work was to apply and extend a previously developed semi-mechanistic exposure–response model for uric acid kinetics to include between-subject variability to verinurad and its combinations with XOIs, and to provide predictions to support future treatment strategies. The model was developed using data from 12 clinical studies from a total of 434 individuals, including healthy volunteers, patients with hyperuricemia, and renally impaired subjects. The model described the data well, taking into account the impact of various patient characteristics such as renal function, baseline fractional excretion of uric acid, and race. The potencies (EC50s) of verinurad (reducing uric acid reuptake), febuxostat (reducing uric acid production), and oxypurinol (reducing uric acid production) were: 29, 128, and 13,030 ng/mL, respectively. For verinurad, symptomatic hyperuricemic (gout) subjects showed a higher EC50 compared with healthy volunteers (37 ng/mL versus 29 ng/mL); while no significant difference was found for asymptomatic hyperuricemic patients. Simulations based on the uric acid model were performed to assess dose–response of verinurad in combination with XOI, and to investigate the impact of covariates. The simulations demonstrated application of the model to support dose selection for verinurad.

Keywords Uric acid · PKPD · Hyperuricemia · Semi-mechanistic modeling · URAT1 · Mixed effects modeling · Verinurad · Febuxostat · Allopurinol

Introduction
Hyperuricemia, defined as elevated serum uric acid (sUA) levels, has been linked to an increased risk of kidney disease, hypertension, coronary heart disease, cardiovascular mortality, and diabetic retinopathy [1–7]. These discoveries raised the question of whether sUA lowering therapy would improve patient outcomes; at present there is no clear and consistent evidence that sUA lowering translates into cardiovascular and renal benefits, with some trials reporting improvement in patients, while others showing no benefit or even worsening [8–10]. Verinurad, which lowers sUA levels, is currently in development in combination with xanthine oxidase inhibitor (XOI) for chronic kidney disease (CKD) and heart failure (HF). The
combination has shown promising results reducing albuminuria, a surrogate marker of early kidney disease [11].

The production of uric acid occurs via purine degradation and is catalyzed by xanthine oxidase (XO), while excretion occurs mainly by the kidneys [12]. Most uric acid is reabsorbed in the proximal tubules by uric acid transporter 1 (URAT1) [13], as evidenced by approximately 5- to tenfold higher fractional excretion (i.e. 50–80%) in individuals with inactivating mutations in the URAT1 gene than normal individuals [14]. In addition to URAT1, solute carrier family 2 facilitated glucose transporter member 9 (GLUT9) and organic iron transporter 4 (OAT4) reabsorb uric acid from the renal tubular lumen back to the systemic circulation.

Hyperuricemia may occur due to either overproduction and/or underexcretion of uric acid. Current options for treating hyperuricemia include inhibitors of uric acid production, such as the XOIs febuxostat and allopurinol, and older uricosurics promoting uric acid excretion (including via URAT1 inhibition) such as benzbrozorone, probenecid, sulfipyrazone, and the selective URAT1 inhibitor lesinurad. Lesinurad 200 mg was approved in combination with allopurinol or febuxostat by the United States Food and Drug Administration (FDA) for treatment of hyperuricemia associated with gout [15].

Verinurad is a novel, selective uric acid reabsorption inhibitor that inhibits URAT1 in the renal tubular lumen, leading to increased urinary excretion of uric acid and decreased sUA levels, and has increased potency for URAT1 compared with lesinurad [16]. Verinurad in combination with a XOI (either febuxostat or allopurinol) has shown effective reduction of sUA levels in patients with hyperuricemia associated with gout [17–19]. Importantly, the combination of verinurad and XOI was more effective in reducing sUA levels than either alone [20, 21]. In addition to intensive serum urate lowering, verinurad and XOI treatment was shown to be safe, with minimal effect on urinary uric acid (uUA) levels in phase 1 and 2 studies in adults with gout [18, 19, 21]. In contrast to verinurad, increased incidence of renal adverse events have been observed with the highest dose (400 mg) of lesinurad in combination with a XOI, possibly due to microcrystallization of uUA in renal tubules [22].

The effect of urate-lowering therapies, such as XOIs and URAT1 inhibitors, may be affected by underlying pathophysiological situations such as impaired renal function. A semi-mechanistic exposure–response model for uric acid dynamics has previously been developed to assess the combined effect of the URAT1 inhibitor lesinurad and a XOI to predict mean response [23]. The aim of the present work was to apply the uric acid model structure to data collected during the verinurad clinical development program and estimate uric acid model parameters, as well as drug effects, on uric acid dynamics. In addition, the previously developed mean response model was extended to a mixed effects model to include between-subject variability on uric acid parameters. A variety of simulations were conducted to support use of the model for dose selection for future studies with verinurad.

Methods

Clinical studies

All available clinical data from studies where modified release (MR4) or extended release (ER8) verinurad formulations were used in the present analysis, comprising 12 clinical studies of verinurad and including single ascending dose (SAD), multiple ascending dose (MAD), drug-drug interaction (DDI), and several phase 2a studies in several patient populations. For a detailed overview of the clinical studies, see Table 1. Sampling schedules for each study are listed in Supplementary materials 1–3. In total, 434 individuals were incorporated in the integrated analysis.

Pharmacokinetic models

Population pharmacokinetic (popPK) models were developed separately for verinurad (modified release [MR4] and extended release formulations [ER8]) and oxypurinol (active metabolite of allopurinol), in order to better capture the complex absorption of each formulation and obtain individual PK parameter estimates for each subject. Details of the popPK models can be found in the Supplementary Material. For febuxostat, a previously published popPK model was used with no modifications [24].

Pharmacodynamic model of uric acid handling

To model the uric acid in circulation and urine, a semi-mechanistic model of uric acid disposition was used as a structural model [23], and is reproduced here for the reader’s convenience. An illustrative graphic of the model is shown in Fig. 1.

The key kinetic processes that constitute mass balance of uric acid in the body are production of uric acid, intestinal clearance, and renal clearance. The rate of change (mg/h) of the amount of uric acid in the systemic compartment A1 (mg) is given by the differential equation:

$$\frac{dA_1}{dt} = R_P - R_I - R_R,$$

where $R_P$ is the production rate, $R_I$ is intestinal elimination rate and $R_R$ is the renal excretion rate. The rate of intestinal elimination of uric acid (mg/h) is described by a first order
Table 1 Overview of clinical data used for analysis

| Study | Description | Subjects | Population | Verinurad doses (mg) | XOI doses (mg) | Reference |
|-------|-------------|----------|------------|---------------------|----------------|-----------|
| RDEA3170-104 | Single and Multiple Dose Study in Japanese Subjects | 48 | Healthy volunteers | 2.5, 5, 10, 15a | – | NCT01872832; [41] |
| RDEA3170-105 | Verinurad and Febuxostat Drug Interaction Study | 23 | Healthy volunteers | 2.5, 10b | 40 mg febuxostat | NCT01883167; [20] |
| RDEA3170-107 | Verinurad and Allopurinol Combination Study in Gout Subjects | 12 | Symptomatic hyperuricemic | 10a | 300 mg allopurinol | NCT02279641; [21] |
| RDEA3170-108 | PK Renal Impairment Study | 31 | Mild, moderate, and severe renal impairment, normal renal function | 15a | – | NCT02219516; [38] |
| RDEA3170-110 | Bioavailability Study | 15 | Healthy volunteers | 10a | – | NCT02336594 |
| RDEA3170-112 | Single and Multiple Dose Study | 40 | Healthy volunteers | 4.5, 6, 12b | – | NCT02608710 |
| RDEA3170-204 | Verinurad and Febuxostat Combination Study | 64 | Symptomatic hyperuricemic | 2.5, 5, 10, 15, 20a | 40, 80 mg febuxostat | NCT02246673; [18] |
| RDEA3170-205 | Verinurad and Febuxostat Combination Study | 72 | Symptomatic hyperuricemic | 2.5, 5, 10, 15a | 10, 20, 40 mg febuxostat | NCT02317861; [19] |
| RDEA3170-206 | Phase 2a Verinurad and Allopurinol Combination Study in Gout Subjects | 41 | Symptomatic hyperuricemic | 2.5, 7.5, 15, 20b | 300 (qd and bid), 600 mg allopurinol | NCT02498652; [17] |
| D5495C00001 | PD DDI with verinurad, febuxostat, and dapagliflozin | 36 | Asymptomatic hyperuricemic | 9b | 80 mg febuxostat | NCT03118739 |
| D5495C00006* | Multiple dose study in Asians/ Chinese | 18 | Healthy volunteers | 12, 24b | 300 mg allopurinol | NCT03836599 |
| D5495C00007 | Ph2a, Verinurad and Febuxostat in Patients With Albuminuria | 60 | T2DM, asymptomatic hyperuricemic, with albuminuria | 9b | 80 mg febuxostat | NCT03118739 |

XOI xanthine oxidase inhibitor

*aUsed for model validation

*aModified release (MR4) formulation

*bExtended release (ER8) formulation

Fig. 1 Schematic view of the verinurad uric acid model with the key processes and drug actions shown. Febuxostat and allopurinol inhibits the production of uric acid while verinurad inhibits the reabsorption (dashed lines).
kinetic process with respect to concentration of uric acid in the systemic compartment $C_{UA}$ (mg/L) according to:

$$R_t = CL_t * C_{UA}$$  \hspace{1cm} (2)

where $CL_t$ is the intestinal clearance of uric acid (L/h). Concentration of uric acid in the systemic compartment is given by:

$$C_{UA} = \frac{A_1}{V_1}$$  \hspace{1cm} (3)

where $V_1$ is the volume of distribution (L).

Inhibition of the production rate by febuxostat or oxy-嘌呤ol is described by a saturable function of drug concentration in plasma with parameters $E_{max}$ and $EC_{50}$ specific to each XOI drug. The value $1 - E_{max}$ corresponds to the maximum possible inhibition of the production rate of uric acid achieved with a very large dose of allopurinol or febuxostat. The value of $EC_{50}$ is the plasma concentration of the drug that results in half-maximal inhibition of the production rate. The rate $k_{in}$ (mg/h) is production rate of uric acid in the absence of drug treatment.

$$R_P = k_{in} \left( 1 - \frac{E_{max} C_x}{EC_{50} + C_x} \right)$$  \hspace{1cm} (4)

where $C_x$ corresponds to the plasma concentration of either febuxostat or oxy-嘌呤ol.

Key kinetic processes that constitute renal handling of uric acid are glomerular filtration of uric acid and renal excretion of uric acid. Uric acid is freely filtered into the kidney from the circulation is denoted $FL_{in}$ (mg/h), which is modelled to be equal to the concentration of uric acid in the systemic compartment multiplied by the glomerular filtration flow rate (GFR). In this work, the GFR is approximated using the CKD-EPI formula [26]. In the following equations, estimated GFR (eGFR) is given in L/h (1 ml/min/1.73 m² = 0.06 L/h) to have consistent units. Hence, the filtration rate of uric acid into the kidney is given by the relationship:

$$FL_{in} = eGFR * C_{UA}$$  \hspace{1cm} (5)

The rate of renal excretion of uric acid is calculated as the product of the input filtration rate and the fractional excretion coefficient (FEUA).

$$R_R = FL_{in} * FEUA = eGFR * C_{UA} * FEUA$$  \hspace{1cm} (6)

Verinurad increases the excretion rate by inhibiting the reabsorption of uric acid back to the circulation. An Emax model is used to describe the stimulating drug action of the FEUA according to the relationship:

$$R_R = eGFR * C_{UA} * \left( FEUA + \frac{E_{max} C_V}{EC_{50} + C_V} \right)$$  \hspace{1cm} (7)

where $C_V$ denotes the plasma concentration of verinurad. The value $FEUA + E_{max}$ is the maximum possible fractional excretion of uric acid achieved with a very large dose of verinurad. The value of $EC_{50}$ is the plasma concentration of verinurad that results in half-maximal inhibition of reabsorption, i.e. when the fractional excretion is $FEUA + E_{max}/2$. The renal excretion rate $R_R$ is the rate of accumulation of uric acid in the bladder and can be indirectly estimated by measuring accumulation of uric acid in final, collected urine.

The full system of differential equations of the model are the following, where $A_1$ is the amount of uric acid (in mg) in the systemic circulation and $A_2$ is the cumulative amount of uric acid (in mg) excreted in urine:

$$\frac{dA_1}{dt} = k_{in} \left( 1 - \frac{E_{max} C_x}{EC_{50} + C_x} \right) - CL_t \frac{A_1}{V_1} - eGFR \frac{A_1}{V_1} \left( FEUA + \frac{E_{max} C_V}{EC_{50} + C_V} \right)$$

$$\frac{dA_2}{dt} = eGFR \frac{A_1}{V_1} \left( FEUA + \frac{E_{max} C_V}{EC_{50} + C_V} \right)$$

$$A_1(0) = \frac{V_1 k_{in}}{CL_t + eGFR * FEUA}$$

$$A_2(0) = 0$$  \hspace{1cm} (8)

where the initial condition $A_1(0)$ is calculated from steady-state assumption (solving the equation $\frac{dA_1}{dt} = 0$), and the initial condition for the cumulative amount in urine, $A_2(0)$, is set to zero.

The baseline concentration of uric acid, assuming steady-state conditions without the presence of drug, is given by the amount in the systemic circulation at baseline, $A_1(0)$, divided by the volume of distribution $V_1$:

$$\frac{C_{UA}}{SS} = \frac{A_1(0)}{V_1} = \frac{k_{in}}{CL_t + eGFR * FEUA}$$  \hspace{1cm} (9)

which has the unit mg/L.

In Aksenov et al. the semi-mechanistic uric acid model was developed as a mean response model, with the aim of describing the mean response in the population [23]. In this work, we consider the extension to a mixed-effects model, with the ability to describe both mean response and variability in the population. In a mixed-effects model, parameters are modeled with statistical distributions to describe variability between individuals. We specified lognormal distributions for model parameters $\theta_i$ as follows:

$$\theta_i = \theta_{pop} \ exp(\eta)$$  \hspace{1cm} (10)

where $\theta_{pop}$ is the typical value of the parameter in the population (median of the population distribution), and $\eta$ is the random effect, normally distributed with mean zero and standard deviation $\omega$. 

 Springer
Residual error model for uric acid in serum and urine had additive and proportional variance components:

\[ y = f + \sqrt{a^2 + (b \times f)^2} \times \varepsilon \]  

(11)

where \( y \) is the observed uric acid in serum or urine, \( f \) is the model prediction, \( a \) is the standard deviation for the additive error component, \( b \) is the standard deviation for the proportional error component and \( \varepsilon \) is distributed independently and normally about mean 0 with variance 1. The residual error model for concentration of uric acid in serum was an additive model (i.e. \( b = 0 \)); for uric acid in urine, a combined additive and proportional model was used.

Development of the integrated uric acid model

The semi-mechanistic model was developed in following steps: first, three popPK models were developed for verinurad, febuxostat, and oxypurinol. As a second step, the individual PK time-profiles (using the empirical Bayes estimates) of the respective drug exposures were used to drive the PD uric acid model.

Discrimination between models such as various combinations of covariates or parameter variability or residual error models, was done by inspection of graphical diagnostics, precision of parameter estimates, and changes in the objective function value provided by NONMEM [27]. Inclusion of correlation between random effects (OMEGA block) was guided by correlation between empirical Bayes Estimates. The adequacy of the models was evaluated using graphical analysis of goodness-of-fit plots and visual predictive checks [28].

Study D5495C00006 was used as a validation study in the current assessment. The reason for this was that in this study, the design included a 7-day allopurinol run-in period and the first urinary samples were collected already after patients were treated with allopurinol monotherapy for 7 days. Therefore, a true baseline of uUA measurements, collected without any treatment, were not available. These measurements are required for accurate estimation of the baseline characteristics and consequently the magnitude of treatment effect. Therefore, the decision was made to use this study as a validation, instead of a part of the modeling dataset. The integrated uric acid model was used to produce visual predictive check plots for study D5495C00006, to assess whether the model can adequately predict results from an external study and thus validating its predictive value.

Model simulations

Two types of simulations were applied: simulation with variability and simulation with uncertainty. Simulations with variability were performed using the estimated parameter values including patient variability. To simulate the individual response, the covariance matrix of the random effects (OMEGA matrix in NONMEM) was sampled for 500 individuals and the 5th, 50th, and 95th quantiles were calculated. For the simulation with uncertainty, a set of variable combinations were simulated (\( n = 500 \)) using mean parameter values and the covariance matrix of model parameters. Next, a model prediction (e.g. sUA reduction or UA renal excretion rate) was derived for each variable combination; this resulted in 500 simulated outcomes that were then used to calculate a median prediction with 5% and 95% quintiles of the distribution. The mean covariate values were used in the simulations; details of specific covariate values used in each simulation can be found in the sections below.

Temporal uric acid response to verinurad in combination with febuxostat

Simulations were performed assuming mean baseline characteristics representative of the CKD/HF patient population: eGFR = 60 mL/min/1.73 m² and asymptomatic hyperuricemia (which resulted in baseline sUA of approximately 8.5 mg/dL and baseline FEUA = 7.7%). A 12 mg ER8 verinurad dose with or without an 80 mg febuxostat dose was used in the simulations.

Dose–response for verinurad in combination with XOI in the CKD/HF population

Simulations were performed assuming mean baseline characteristics representative of the CKD/HF patient population as used for the temporal uric acid response to verinurad in combination with febuxostat. A dose range between 0 and 15 mg for the verinurad ER8 formulation, in combination with either 80 mg febuxostat or 300 mg allopurinol was simulated for generating dose–response curves.

Assessment of the impact of covariates on the PK/PD of verinurad

For the assessment of covariates, each covariate was compared with a typical patient using the following typical values: eGFR of 60 mL/min/1.73 m², body weight of 80 kg, and non-Asian race. The following range of covariates were explored: Asian versus non-Asian; eGFR 45, 60, and 90 mL/min/1.73 m²; body weight 50, 80, and 100 kg. A 12 mg ER8 verinurad dose combined with 80 mg febuxostat was used in the simulations.
Selecting the dose of XOI for combination with verinurad

Simulations were performed assuming the following baseline characteristics: eGFR 60 mL/min/1.73 m$^2$, asymptomatic hyperuricemia (which resulted in a baseline sUA of approximately 8.5 mg/dL and baseline FEUA = 7.7%), and non-Asian race. A 12 mg ER8 verinurad dose combined with the following febuxostat doses were used in the simulations: 0, 20, 40, 60, and 80 mg.

Software

The popPK models and the uric acid model were estimated using NONMEM 7.3.0 [27]. For the popPK models the first order conditional estimation (FOCE) method was used, while the first order conditional estimation with interaction (FOCEI) was used for the uric acid model. R, version 3.5.1 [29] was used for the exploratory analyses. The R package nonmem2R, version 0.2.1 was used to produce visual predictive checks and goodness-of-fits plots [30]. The R package mrgsolve, version 0.8.12 [31] was used to perform the model simulations.

Results

Subject characteristics

A summary of the demographics and baseline characteristics of the subjects included in the analysis can be found in Table 2. The mean sUA and eGFR values were 7.6 mg/dL and 97 mL/min/1.73 m$^2$, respectively. Subjects included in the analysis were mostly men (nearly 97% of the overall population) and 43% and 22% of patients had symptomatic and asymptomatic hyperuricemia, respectively. Overall, there was a wide spread in baseline sUA, with a range between 4 and 13.3 mg/dL.

Pharmacokinetics of verinurad, febuxostat, and oxypurinol

PopPK models developed for verinurad and oxypurinol (allopurinol active metabolite) fitted data well, as judged by goodness of fit plots and precision of parameter estimates.

Two separate PK models were developed for verinurad: one for modified release (MR4) and one for extended release (ER8) formulations, with different formulation principles (MR4 as a tablet and ER8 as a capsule) and bioavailability. Both models were two-compartmental disposition models with an absorption comprising of zero-order infusion into the dosing compartment and sequential first-order absorption. eGFR and body weight were found to be significant covariates on verinurad clearance.

For oxypurinol, a two-compartmental disposition model with first-order absorption was used. eGFR was found to be covariate on clearance, while body weight was used for central volume of distribution. As expected, verinurad was found to have an impact on oxypurinol exposure (concomitant intake of verinurad reduces oxypurinol exposure) [21]. Detailed results from popPK modeling for verinurad and oxypurinol, including final parameter estimates and goodness-of-fit plots, can be found in the Supplementary Material.

Estimation of model parameters

The estimated parameters for the final model are listed in Table 3. The covariate effect on FEUA was modelled as: 

$$\text{FEUA} = \text{FEUA}_\text{Typ} \times (1 + \text{HYPERFEUA}) \times (1 + \text{ASIANFEUA}),$$

where FEUA_Typ corresponds to FEUA in healthy volunteers and HYPERFEUA and ASIANFEUA are the covariate estimates corresponding to hyperuricemic patients (either symptomatic or asymptomatic) and Asians, respectively.

The covariate effect on verinurad EC50 was modelled as:

$$\text{EC50} = \text{EC50}_\text{Typ} \times (1 + \text{HYPEREC50}),$$

where EC50_Typ corresponds to EC50 in healthy volunteers and HYPEREC50 corresponds to the covariate estimate for symptomatic hyperuricemic (gout) patients. Parameters were estimated with adequate precision; relative standard errors (RSE) were less than 35%, with the majority of parameters having RSE below 30%. Despite some evidence of a misfit to uUA data and overprediction of the steady state sUA data, in general the goodness-of-fit and visual predictive check plots support the adequacy of the model for the intended purpose of supporting planning and decision making for future studies (Supplementary Material 4).

Uric acid baseline fractional excretion, FEUA, was found to be different between healthy volunteers and patients with hyperuricemia. Interestingly, baseline FEUA also differed between patients with symptomatic (gout) and asymptomatic hyperuricemia. The baseline value was higher in healthy volunteers (9.1%) compared with the symptomatic (5.6%) and asymptomatic (7.7%) hyperuricemic patients. Moreover, Asian subjects were found to have a slightly lower fractional excretion of uric acid compared with non-Asians (4.3% compared with 5.6% in symptomatic hyperuricemic patients). It should be noted...
that only patients from study D5495C00001 were used to estimate the separate FEUA value for asymptomatic hyperuricemic patients. Asymptomatic hyperuricemics were also included in study D5495C00007, however, no urine collection was performed in this study and therefore it was not possible to reliably estimate FEUA for those patients.

Emax models were able to adequately describe the effects of verinurad, febuxostat, and oxypurinol. It was not possible to reliably estimate the maximum effects (Emax) of each drug using current data. Therefore, those parameters were fixed; the maximum effects for febuxostat and oxypurinol were fixed to the same values as in Aksenov et al. 2018 (1 and 0.84 for febuxostat and oxypurinol Emax, respectively; this corresponds to the maximum inhibition of uric acid production) [23]. For verinurad, the Emax parameter corresponds to the maximum increase in fractional excretion of uric acid; this value was fixed to the 0.7, consistent with FEUA values reported in people with loss of function mutations in URAT1 [14, 32]. The potencies (EC50s) of verinurad, febuxostat, and oxypurinol were: 29.3, 128, and 13,030 ng/mL, respectively. It was explored whether potency was different between healthy volunteers and hyperuricemic patients. For verinurad, symptomatic hyperuricemic (gout) patients showed a higher EC50 compared with healthy volunteers (37.3 ng/mL versus 29.3 ng/mL); for the asymptomatic hyperuricemic patients (studies D5495C00001 and D5495C00007), no significant difference versus healthy volunteers could be established. For febuxostat, no differences in EC50 were identified between healthy volunteers and hyperuricemic patients. For oxypurinol, only studies in hyperuricemic patients (RDEA3170-107 and RDEA3170-206) were available for model building, therefore, potential differences could not be assessed.

Study D5495C00006, a multiple dose study in healthy Asian volunteers treated with either 12 mg or 24 mg verinurad dose combined with 300 mg allopurinol, was not included in the modeling, and was instead used as a validation study. The model was found to predict the steady-

### Table 2 Summary of baseline characteristics of patients included in the analysis

| Study          | n  | Age (years) median (min, max) | Body weight (kg) median (min, max) | eGFR (ml/min/1.73 m²) median (min, max) | sUA (mg/dL) median (min, max) | Sex (males) n (%) | Race: Caucasian n (%) | Race: Black n (%) | Race: Asian n (%) | Race: other n (%) |
|----------------|----|-------------------------------|-----------------------------------|----------------------------------------|-------------------------------|-------------------|----------------------|-------------------|-------------------|------------------|
| D5495C00001    | 36 | 41 (20, 63)                  | 85.7 (57.7, 121.3)               | 91.4 (52.8, 128)                   | 7.1 (5.8, 9.6)               | 35 (97.2)         | 14 (38.9)                        | 17 (47.2)         | 2 (5.6)           | 3 (8.3)          |
| D5495C00006    | 21 | 38 (27, 48)                  | 72.25 (58.75, 90.75)             | 103 (70.4, 119.1)                 | 6 (4.2, 10.7)                | 19 (90.5)         | 0 (0)                             | 0 (0)             | 21 (100)          | 0 (0)            |
| D5495C00007    | 32 | 62 (43, 79)                  | 90.4 (52.6, 136.3)              | 55.9 (31.6, 109.9)                | 7.5 (6, 13.3)                | 22 (68.8)         | 22 (68.8)                         | 6 (18.8)          | 3 (9.4)           | 1 (3.1)          |
| RDEA3170-104   | 48 | 31.5 (21, 53)                | 70.4 (54.9, 101.7)              | 113.4 (78, 138.3)                | 5.7 (4, 8.1)                 | 48 (100)          | 5 (10.4)                          | 3 (6.2)           | 40 (83.3)         | 0 (0)            |
| RDEA3170-105   | 23 | 35 (21, 48)                  | 87.9 (65.8, 115.9)              | 98.3 (75.7, 117.7)               | 6.4 (5, 9.1)                 | 23 (100)          | 15 (65.2)                         | 7 (30.4)          | 0 (0)             | 1 (4.3)          |
| RDEA3170-107   | 12 | 51.5 (29, 69)                | 99.7 (80.9, 126.3)              | 84.3 (54.1, 102.9)               | 8.6 (7.1, 9.6)               | 12 (100)          | 7 (58.3)                          | 4 (33.3)          | 0 (0)             | 1 (8.3)          |
| RDEA3170-108   | 31 | 61 (35, 81)                  | 82.6 (59, 122)                  | 74 (12.3, 106.1)                 | 6.7 (4.1, 12.4)              | 31 (100)          | 23 (74.2)                         | 7 (22.6)          | 0 (0)             | 1 (3.2)          |
| RDEA3170-110   | 15 | 44 (25, 62)                  | 90.9 (65.4, 129.4)              | 99.2 (74.9, 134.3)               | 5.3 (4.4, 6.5)               | 15 (100)          | 11 (73.3)                         | 2 (13.3)          | 0 (0)             | 2 (13.3)         |
| RDEA3170-112   | 40 | 35.5 (24, 56)                | 86.1 (59.2, 126.8)              | 99.6 (78.1, 131.6)               | 5.7 (4.2, 7.4)               | 40 (100)          | 22 (55)                           | 17 (42.5)         | 1 (2.5)           | 0 (0)            |
| RDEA3170-204   | 64 | 48 (29, 71)                  | 98.65 (63.8, 138.7)             | 89.7 (57.4, 121.1)               | 8.8 (5.5, 12.3)              | 64 (100)          | 43 (67.2)                         | 7 (10.9)          | 14 (21.9)         | 0 (0)            |
| RDEA3170-205   | 72 | 46 (21, 67)                  | 75.45 (58.3, 115.6)             | 105.6 (76.8, 133.2)              | 8.6 (7.5, 12.7)              | 72 (100)          | 0 (0)                             | 0 (0)             | 72 (100)          | 0 (0)            |
| RDEA3170-206   | 40 | 48 (28, 74)                  | 95.5 (63.1, 147.6)              | 89.9 (55.1, 125.6)               | 9 (6.7, 10.7)                | 39 (97.5)         | 30 (75)                           | 6 (15)            | 4 (10)            | 0 (0)            |
| All subjects   | 434| 45 (20, 81)                  | 84 (52.6, 147.6)                | 97 (12.3, 138.3)                 | 7.6 (4, 13.3)                | 420 (96.8)        | 192 (44.2)                        | 76 (17.5)         | 157 (36.2)        | 9 (2.1)          |

* eGFR estimated glomerular filtration rate, sUA serum uric acid
state data from this study well, as judged by visual predictive check plots (see Supplementary Material). It should be acknowledged that one limitation of the validation is that study D5495C00006 did not include measurements of uric acid at an untreated baseline.

**Temporal uric acid response to verinurad in combination with febuxostat**

Figure 2 shows model simulations for 1-week treatment with once-daily dosing of either verinurad alone (12 mg dose of ER8 formulation), febuxostat alone (80 mg), and a combination of two drugs (12 mg verinurad and 80 mg febuxostat), for a typical patient with an eGFR of 60 mL/min/1.73 m² and baseline sUA of 8.5 mg/dL. The sUA reduction following combination treatment is considerably larger compared with the effect of either of the drugs alone.

Verinurad, as a URAT1 inhibitor that promotes renal excretion of uric acid, has a direct effect on FEUA. This is illustrated in the bottom right plot in Fig. 2, where FEUA increases following either verinurad monotherapy or verinurad in combination with XOI. In both scenarios, FEUA can be seen to fluctuate on average between approximately 19.4% and 35.5% during the 24 h interval at steady state (when baseline FEUA is ~7.7%). The effect on FEUA is the same regardless of verinurad monotherapy or its combination with a XOI, since a XOI has no impact on FEUA.

Daily fluctuations in FEUA following verinurad treatment are accompanied by fluctuations in uric acid renal excretion rate (bottom middle plot). If verinurad is given as monotherapy, renal excretion rate at steady-state is considerably increased. During steady state, it can fluctuate on average between 27.1 and 47.7 mg/h. When verinurad is administered with XOI, renal excretion rate at steady-state

---

**Table 3** Estimated parameter values of the verinurad and XOI uric acid model

| Parameter                                      | Typical value | RSE % |
|-----------------------------------------------|---------------|-------|
| $k_{in}$, (mg/h)                              | 43.78         | 1.75  |
| FEUA, healthy volunteers                      | 0.0906        | 3.18  |
| CL$_d$, (L/h)                                 | 0.2272        | 12.8  |
| $V_l$, uric acid (L)                          | 14.11         | 0.661 |
| Verinurad EC50 (ng/mL)                        | 29.40         | 4.73a |
| Febuxostat EC50 (ng/mL)                       | 128.0         | 7.16a |
| Oxyapurinol EC50 (ng/mL)                      | 13,030        | 12a   |
| Residual error, additive, serum               | 0.4107        | 0.158 |
| Residual error, additive, urine               | 3.054         | 0.537 |
| Residual error, proportional, urine           | 0.3806        | 0.371 |
| Residual error, serum, study D5495C00006      | 0.9524        | 2.4   |
| FEUA covariate, asymptomatic hyperuricemic    | -0.1501       | 32.2  |
| FEUA covariate, symptomatic hyperuricemic (gout) | -0.3787       | 6.06  |
| FEUA covariate, Asians                        | -0.2322       | 11.5  |
| Verinurad EC50 covariate, symptomatic hyperuricemic (gout) | 0.2677 | 33.5 |
| $k_{in}$, IIV (CV%)                           | 27.76         | 3.34  |
| FEUA, IIV, (CV%)                              | 42.54         | 3.98  |
| Verinurad EC50, IIV, (CV%)                    | 57.00         | 3.05  |
| Febuxostat EC50, IIV, (CV%)                   | 89.96         | 3.40  |
| Oxyapurinol EC50, IIV, (CV%)                  | 65.44         | 9.66  |
| Off diagonal element production rate—FEUA, (cor) | 0.761         | 4.20  |

The covariate effect on FEUA was modelled as: $FEUA = FEUA_{TYP} \times (1 + HYPERFEUA) \times (1 + ASIANFEUA)$, where $FEUA_{TYP}$ corresponds to FEUA in healthy volunteers and HYPERFEUA and ASIANFEUA are the covariate estimates corresponding to hyperuricemic (either symptomatic or asymptomatic) and Asians, respectively.

The covariate effect on verinurad EC50 was modelled as: $EC50 = EC50_{TYP} \times (1 + HYPEREC50)$, where $EC50_{TYP}$ corresponds to EC50 in healthy volunteers and HYPEREC50 corresponds to the covariate estimate for symptomatic hyperuricemic (gout) patients.

$CL_d$ intestinal clearance of uric acid, $FEUA$ fractional excretion uric acid (here, reported as fraction), $HYPEREC50$ verinurad EC50 covariate in symptomatic hyperuricemic patients, $IIV$ interindividual variability, $k_{in}$ uric acid production rate, $RP$ uric acid production rate, RSE relative standard error, $V_l$ volume of distribution.

$^a$Estimated on log-scale and reported as CV%
is reduced compared with verinurad monotherapy; the daily fluctuations are between 13.8 and 21.3 mg/h and the maximum renal excretion rate at steady state is similar to the value at baseline (approximately 21.3 mg/h compared with 24.3 mg/h, respectively). The full effect of combination treatment is achieved after a few days of administration, once verinurad and XOI exposures have reached steady-state; maximum renal excretion rate is initially increased to approximately 66.2 mg/h on day 1 and this value is reduced to 32.4, 23.8, and 21.9 mg/h on days 2, 3, and 4, respectively. At day 5, the value reaches approximately 21.3 mg/h and continues to stay at this level (bottom middle plot of Fig. 2).

**Dose–response for verinurad in combination with a XOI in CKD and HF patients**

Figure 3 shows model-predicted relationship between verinurad dose and several uric acid responses; 24 h average FEUA, maximum UA renal excretion rate, and maximum sUA reduction. A clear dose–response can be observed for all endpoints. In this simulation, verinurad is always combined with the same XOI dose (here, 80 mg febuxostat or 300 mg allopurinol); this includes dose 0 of verinurad, which consequently corresponds to XOI monotherapy. For reference, placebo response was also added to all plots, to highlight the difference of the verinurad/XOI combination treatment compared with baseline conditions (i.e. no drug).

It should be emphasized that dose–response relationships may be different if alternative baseline patient characteristics are assumed (i.e. baseline eGFR and FEUA). For the simulation presented in Fig. 3, baseline characteristics are used which correspond to patients anticipated in the current CKD and HF development program for verinurad (eGFR of 60 mL/min/1.73 m² and baseline FEUA of 7.7%, which correspond to the population mean FEUA for asymptomatic hyperuricemic patients).
FEUA (%)  
Average over 24h at steady-state

max sUA reduction (%)  
% change from baseline at steady-state

max UA renal excretion rate (mg/h)  
at steady-state
The semi-mechanistic exposure–response model was successfully used to describe data from several phase 1 and phase 2a studies in the clinical development program for verinurad. In the work presented here, an existing uric acid model structure was used as a starting point for model development [23]. To extend the model, interindividual variability was included to explore the impact of individual covariates on the pharmacodynamics and safety of verinurad.

The parameter estimates related to uric acid dynamics were similar as reported previously [23], supporting the ability to recover parameters of uric acid disposition equally well with either drug treatment, as both lesinurad and verinurad affect uric acid disposition in the same way through URAT1 inhibition [16]. The potency of verinurad (EC50) was found to be somewhat higher in hyperuricemic patients, compared with healthy volunteers, in line with the results shown for lesinurad [23]. In the current model, febuxostat potency (EC50) was not found to be significantly different between healthy subjects and hyperuricemic patients, even though this was reported previously [23].

FEUA variability

Baseline FEUA was found to be higher in healthy subjects compared with patients with hyperuricemia, in agreement with previous reports [33]. In addition, we showed a difference in FEUA between two types of hyperuricemic patients: symptomatic (gout) and asymptomatic (patients included in D5495C00001 study), with symptomatic patients having the lowest FEUA value. Interestingly, Asian subjects were found to have somewhat lower FEUA compared with non-Asians; however genetic data are needed to unequivocally attribute this effect to Asian race,
such as higher prevalence in individuals of Asian descent of certain polymorphisms in the URAT1 gene. Polymorphisms in the URAT1 gene have been linked to hyperuricemia in Asian populations, although further elucidation of the precise mechanism of the effect of these polymorphisms on URAT1 function is required [34, 35]. If confirmed, lower FEUA may be due to a slightly higher eGFR in the Asian subjects in our studies (thus Asian race may confound the effect of eGFR explicitly included in our model) or different purine content in the Asian diet.

### Applications of this model

The strength of this uric acid model is the ability to simultaneously describe two different endpoints: sUA reduction (related to efficacy) and uUA excretion (related to safety). This is valuable when selecting an optimal dose during drug development, as it allows a quantitative assessment of the balance between efficacy and safety. A safety concern with URAT1 monotherapy is serum creatinine elevation, which has been partly attributed to an increased urinary renal excretion rate of uric acid leading to its precipitation and microcrystallization in renal tubules [22]. To mitigate this risk, verinurad is always combined
with a XOI, leading to a reduction in renal excretion rate. With a semi-mechanistic model, which can quantitatively describe serum acid dynamics, it is possible to simulate various scenarios. For example, different dose combinations (including those not tested in a clinical setting) of verinurad and XOI can be simulated to identify the optimal dosing regimen, e.g. one that brings uUA excretion to baseline (as illustrated in Fig. 5).

Another valuable application of this model is the opportunity to predict maximum sUA reduction and maximum uUA excretion for individual subjects in phase 2 and phase 3 studies using sUA and uUA data, even if the data is sparse. Timing these observations without modeling maxima of serum and urine UA is challenging in such a setting (i.e. large trials). For example, maximum reduction of uric acid occurs rather late in the day (if the dose is taken in the
morning), as observed in simulated time profiles in Fig. 2. Therefore, sample collection would ideally need to take place in the afternoon, which may often not be feasible. Additionally, there remains some discussion regarding whether maximal uric acid excretion rate is a predictor of renal safety; a surge in uUA excretion may lead to crystallization and subsequent tubular luminal obstruction, resulting in acute kidney injury [36]. Currently, the likelihood of uric acid crystallization is reduced through increasing fluid intake [37] and measurement of maximal uric acid excretion rate requires collection of urine throughout the day in regular time intervals, which is difficult to obtain in large phase 2 or 3 studies.

### Impact of covariates

The exploration of covariate impact on verinurad and XOI treatment showed that none of the covariates investigated had a clinically relevant impact on efficacy and safety (as demonstrated in Fig. 4 for the combination of 12 mg verinurad and 80 mg febuxostat). This supports the use of the same doses of verinurad and XOI given in combination for all patients, regardless of renal function, body weight and race (Asian vs non-Asian) in the current development program. The similar reduction in sUA from baseline with the same dose of verinurad for low and normal renal function is related to the increase in UA renal clearance with higher verinurad exposure. This increase with higher verinurad exposure is counteracted by decreased renal clearance due to lower eGFR.

### Limitations

It should be highlighted that the conclusions of the model and subsequent dose recommendations apply to patients with renal function and body weight within the range studied here and it cannot be excluded that PK and/or PD may be affected to a clinically relevant extent in patients with different characteristics. For example, one limitation of the current work is the inclusion of a limited number of patients with severe renal impairment (eGFR < 30 mL/ min/1.73 m²). Therefore, this model may not reflect the exposure–response relationship in patients with severely impaired kidney function, as our current model overpredicts sUA and uUA in the renal impairment study RDEA3170-108 [38]. One explanation for this overprediction may be a higher FEUA in renally impaired patients, which in turn affects sUA level and the effect of the treatment. However, URAT1 inhibition becomes ineffective at very low eGFR, and therefore patients with eGFR below 25 ml/min/1.73 m² are not included in the ongoing phase 2b studies. Examining the assumptions of this model with regards to the effects of renal impairment, such as the assumption that renal impairment is reflected only in a decreased eGFR (and FEUA is unchanged), may be one direction for evolving the model in the future. A phase 2b study of verinurad in patients with CKD (NCT03990363) will provide further data on URAT1 inhibition and the effects of renal impairment in this patient population.

Overestimation of urinary UA data for some of the studies is seen in subjects who have the highest amounts of cumulative urinary UA. This corresponds to the long urine collection interval overnight, suggesting that the rate of uUA excretion is not constant over the collection period. This may need to be examined further and incorporated into future models. Additionally, the ability to accurately describe the dose–response component of allopurinol is limited due to data availability; the only doses of allopurinol studied in the verinurad clinical program are 300 mg and 600 mg, both of which result in close to maximum effect on sUA reduction. Although the model can describe the steady-state effect of 300 mg allopurinol adequately, the extrapolation to lower doses may not be reliable.

### Benefits of verinurad

While comparison of verinurad and lesinurad are out of scope of this paper, we note that verinurad can be predicted to have improved serum UA lowering and reduced urine UA excretion compared with lesinurad for two reasons: greater potency of verinurad for the URAT1 transporter and slow absorption when given in the extended release formulation [16]. Firstly, higher potency allows for low doses of verinurad to be used clinically. Secondly, reducing the absorption rate of verinurad as a strategy to reduce potential renal-damaging effects of UA excretion, while still maintaining serum UA lowering, is based on no change to the AUC at steady state while reducing Cmax. Lower Cmax reduces the maximum UA urinary excretion rate compared with the immediate release formulation. The maintained AUC of verinurad drives continuing excretion of UA and maintains serum UA lowering.

### Adherence

Modelling of dual urate-lowering therapy has suggested that poor adherence to therapy may negatively impact the efficacy and safety profiles; when dosing is restarted following missed doses, uUA excretion is increased [39]. A fixed-dose combination has been developed, so that patients will always receive both the URAT1 inhibitor and the XOI.
Future expansions of the model

It is worth mentioning that sUA levels fluctuate during 24 h at baseline, i.e. without any drug treatment. This may indicate the presence of circadian rhythm and/or impact of diet, which has been previously reported in literature [40]. The assessment of sUA circadian rhythm was not within the scope of the current work, and could be an expansion of the current model. Additional information may be required to accurately describe such daily sUA variation, for example differences in food intake that may affect purine metabolism.

Conclusions

The semi-mechanistic exposure–response model for veriurad combined with either febuxostat or allopurinol was successfully developed and described the data well, taking into account impact of various patient characteristics, such as renal function, baseline fractional excretion of uric acid, and race. Simulations demonstrate how this model can be used to justify dose selection in patient subpopulations. The model can support clinical development by simulating different scenarios with respect to treatment and/or patient populations.

Acknowledgements The authors would like to thank Fredrik Erlsandsson and Michael Gillen for valuable discussions, as well as Huan Liu and Srinivas Bachina for programming support. Moreover, the authors also want to thank Jesse Hall, James Mackay and colleagues at former Ardea Biosciences for valuable discussions. Medical writing support was provided by Jessica Gorrill, MSc and editorial support was provided by Rachael Cazaly all of Core Medica, London, UK, supported by AstraZeneca according to Good Publication Practice guidelines (Link). The Sponsor was involved in the study design, collection, analysis, and interpretation of data, as well as data checking of information provided in the manuscript. However, ultimate responsibility for opinions, conclusions, and data interpretation lies with the authors.

Author contributions JL, MS, DR, SA, UE, SJ and JP wrote the manuscript. JL, MS, JP, DR were involved in data analysis.

Declarations

Conflict of interest JL, MS, DR, UE, SJ, and JP are employees of AstraZeneca. JL and JP own AstraZeneca stock or stock options. SA is currently an employee of the Novartis Institutes for BioMedical Research, Cambridge, MA.

Ethical approval All studies conducted in accordance with the relevant articles of the “Declaration of Helsinki” and International Conference on Harmonisation Good Clinical Practice (ICH GCP) consolidated guidelines. All patients provided written informed consent before study participation.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Heinig M, Johnson RJ (2006) Role of uric acid in hypertension, renal disease, and metabolic syndrome. Cleve Clin J Med 73(12):1059–1064. https://doi.org/10.3949/ccjm.73.12.1059
2. Ford ES, Li C, Cook S, Choi HK (2007) Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 115(19):2526–2532. https://doi.org/10.1161/CIRCULATIONAHA.106.657627
3. Obermayer RP, Temml C, Gutjahr G, Knechtlitscher M, Ober-bauer R, Klausner-Braun R (2008) Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 19(12):2407–2413. https://doi.org/10.1681/ASN.20080101080
4. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA (2010) Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res 62(2):170–180. https://doi.org/10.1002/acr.20065
5. Shao Y, Shao H, Sawney MS, Shi L (2019) Serum uric acid as a risk factor of all-cause mortality and cardiovascular events among type 2 diabetes population: meta-analysis of correlational evidence. J Diabetes Complications 33(10):107409. https://doi.org/10.1016/j.diabcomp.2019.07.006
6. Thounaojam MC, Montemari A, Powell FL, Malla P, Gutsaeva DR, Bachettoni A, Ripandelli G, Repossi A, Tawfik A, Martin PM, Facchiano F, Bartoli M (2019) Monosodium urate contributes to retinal inflammation and progression of diabetic retinopathy. Diabetes 68(5):1014–1025. https://doi.org/10.2337/db18-0912
7. Alappan U, Alappan R (2020) Symptomatic hyperuricemia (gout) patients have higher occurrence of cardiovascular and coronary artery disease. Paper presented at the National Kidney Foundation
8. Kanbay M, Afsar B, Sariopol D, Dincer N, Erden N, Yilmaz O, Sag AA, Kuwabara M, Cherney D, Rossignol P, Ortiz A, Covic A (2020) Effect of uric acid-lowering agents on cardiovascular outcome in patients with heart failure: a systematic review and meta-analysis of clinical studies. Angiology 71(4):315–323. https://doi.org/10.1177/0003319719897509
9. Sato Y, Feig DI, Stack AG, Kang DH, Lanasa MA, Eijaz AA, Sanchez-Lozada LG, Kuwabara M, Borghi C, Johnson RJ (2019) The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD. Nat Rev Nephrol. https://doi.org/10.1038/s41581-019-0174-z
10. Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, Clarke P, Dalbeth N, Day RO, de Zoya JR, Douglas B, Fauli R, Harris DC, Hawley CM, Jones GRD, Kanelis J, Palmer SC, Perkovic V, Rangan GK, Reidlinger D, Robison L, Walker RJ, Walters G, Johnson DW (2020) Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med 382(26):2504–2513. https://doi.org/10.1056/NEJMoa1915833
11. Stack AG, Dronamraju N, Parkinson J, Johansson S, Johnson E, Erlandsson F, Terkeltaub R (2020) Effect of intensive urinary lowering with combined verinurad and febuxostat on albuminuria in patients with type 2 diabetes: a randomized trial. Am J Kidney Dis. https://doi.org/10.1053/j.ajkd.2020.09.009

12. Hediger MA, Johnson RJ, Miyazaki H, Endou H (2005) Molecular physiology of urate transport. Physiology 20:125–133. https://doi.org/10.1152/physiol.00039.2004

13. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Ota T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H (2002) Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417(6887):447–452. https://doi.org/10.1038/nature742

14. Dinour D, Bahn A, Ganon L, Ron R, Geifman-Holtzman O, Knecht A, Gaffer U, Rachamimov R, Sela BA, Burckhardt G, Holtzman EJ (2011) URAT1 mutations cause renal hypouricemia type 1 in Iraqi Jews. Nephrol Dial Transplant 26(7):2175–2181. https://doi.org/10.1093/ndt/gfq722

15. AstraZeneca (2015) ZURAMPIC highlights of prescribing information. Accessed Dec 2020

16. Tan PK, Liu S, Gunic E, Miner JN (2017) Discovery and characterization of URAT1 for the treatment of hyperuricemia and gout. Sci Rep 7(1):665. https://doi.org/10.1038/s41598-017-00706-7

17. Fleischmann R, Winkle P, Miner JN, Yan X, Hicks L, Valdez S, Hall J, Liu S, Shen Z, Gillen M, Hernandez-Illas M (2018) Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. RMD Open 4(1):e000584. https://doi.org/10.1136/rmdopen-2017-000584

18. Fleischmann R, Winkle P, Hall J, Valdez S, Liu S, Yan X, Hicks L, Lee C, Miner JN, Gillen M, Hernandez-Illas M (2018) Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study. RMD Open 4(1):e000647. https://doi.org/10.1136/rmdopen-2018-000647

19. Shiramoto M, Liu S, Shen Z, Yamamoto A, Gillen M, Ito Y, Hall J (2018) Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricemia: a phase 2a, open-label study. Rheumatology 57(9):1602–1610. https://doi.org/10.1093/rheumatology/key100

20. Hall J, Gillen M, Yang X, Shen Z (2019) Pharmacokinetics, pharmacodynamics, and tolerability of concomitant administration of verinurad and febuxostat in healthy male volunteers. Clin Pharmacol Drug Dev 8(2):179–187. https://doi.org/10.1002/cpdd.463

21. Kankam M, Hall J, Gillen M, Yang X, Shen Z, Lee C, Liu S, Miner JN, Walker S, Clauson V, Wilson D, Nguyen M (2018) Pharmacokinetics, pharmacodynamics, and tolerability of concomitant multiple dose administration of verinurad (RDEA3170) and allopurinol in adult male subjects with gout. J Clin Pharmacol 58(9):1214–1222. https://doi.org/10.1002/jcph.11119

22. Terkeltaub R, Saag KG, Goldfarb DS, Baumgartner S, Schechter BM, Valiyil R, Jalal D, Pillinger M, White WB (2019) Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. Rheumatology 58(1):61–69. https://doi.org/10.1093/rheumatology/key245

23. Aksenov S, Peck CC, Eriksson UG, Stanski DR (2018) Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics. Physiol Rep 6(5):13614. https://doi.org/10.14814/phy2.13614

24. Rekic D, Johansson S, Leander J (2020) Higher febuxostat exposure observed in Asian compared with Caucasian subjects independent of bodyweight. Clin Pharmacokinet. https://doi.org/10.1007/s40262-020-00943-6

25. Bobulescu IA, Moe OW (2012) Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis 19(6):358–371. https://doi.org/10.1033/ackd.2012.07.009

26. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, Ckd Epi (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006

27. Beal S, Sheiner L, Boeckmann A, Bauer R (2009) NONMEM users guides (1989–2009). ICON Development Solutions, Ellicott City, MD, USA

28. Ichida K, Hosoyamada M, Kamatani N, Kamitsuji S, Hisatome I, Shibasaki T, Hosoya T (2008) Age and origin of the G774A mutation in SLC22A12 causing renal hypouricemia in Japanese. Clin Genet 74(3):243–251. https://doi.org/10.1111/j.1399-0004.2008.01021.x

29. Hyndman D, Liu S, Miner JN (2016) Urate handling in the human body. Curr Rheumatol Rep 18(6):34. https://doi.org/10.1007/s11926-016-0587-7

30. Shima Y, Teruya K, Ohta H (2006) Association between intronic SNP in urate-anion exchanger gene, SLC22A12, and serum uric acid levels in Japanese. Life Sci 79(23):2234–2237. https://doi.org/10.1016/j.lfs.2006.07.030

31. Cho SK, Kim S, Chung JY, Lee CH (2015) Discovery of URAT1 SNPs and association between serum uric acid levels and URAT1. BMJ Open 5(11):e009360. https://doi.org/10.1136/bmjopen-2015-009360

32. Hall J, Gillen M, Yang X, Shen Z (2017) Serum uric acid and acute kidney injury: a mini review. J Adv Nephrol Nephrol 0.8.12. https://CRAN.R-project.org/package=mrgosolve. Accessed Aug 2020

33. Ichida K, Hosoyamada M, Kamatani N, Kamitsuji S, Hisatome I, Shibasaki T, Hosoya T (2008) Age and origin of the G774A mutation in SLC22A12 causing renal hypouricemia in Japanese. Clin Genet 74(3):243–251. https://doi.org/10.1111/j.1399-0004.2008.01021.x

34. Boase A, Monk RD, Bushinsky DA (2016) Kidney stones. In: Melmed S, Larsen PR, Polonsky KS, Kronenberg HM (eds) Williams textbook of endocrinology, 13th edn. Elsevier, Philadelphia, pp 1365–1384

35. Smith WB, Hall J, Berg JK, Kazimir M, Yamamoto A, Walker S, Lee CA, Shen Z, Wilson DM, Zhou D, Gillen M, Marbury TC (2018) Effect of renal impairment on the pharmacokinetics and pharmacodynamics of verinurad, a selective uric acid reabsorption inhibitor. Drug Invest 38(8):703–713. https://doi.org/10.1007/s40261-018-0652-2

36. Hill-McManus D, Soto E, Marshall S, Lane S, Hughes D (2018) Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout. Br J Clin Pharmacol 84:142–152

37. Singh R, Kumar M, Mishra DN, Singh AK, Singh RK, Mahdi AA, Gierke CL, Cornelissen G (2019) Effect of gender, age, diet and smoking status on the circadian rhythm of serum uric acid of healthy indians of different age groups. Indian J Clin Biochem 34(2):164–171. https://doi.org/10.1007/s11926-019-0724-8

38. Hall J, Gillen M, Liu S, Miner JN, Valdez S, Shen Z, Lee C (2018) Pharmacokinetics, pharmacodynamics, and tolerability of...
verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects. Drug Des Devel Ther 12:1799–1807. https://doi.org/10.2147/DDDT.S152659

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.